Zynex (NASDAQ:ZYXI) Given New $16.00 Price Target at HC Wainwright

Zynex (NASDAQ:ZYXI) had its price target decreased by HC Wainwright from $21.00 to $16.00 in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Zynex’s Q1 2025 earnings at $0.10 EPS and Q2 2025 earnings at $0.11 EPS.

Separately, Royal Bank of Canada reissued an outperform rating and issued a $15.00 price target on shares of Zynex in a research report on Friday, June 14th.

Zynex Stock Performance

Shares of ZYXI opened at $8.93 on Friday. Zynex has a one year low of $6.88 and a one year high of $13.77. The company has a 50-day moving average of $9.55 and a two-hundred day moving average of $11.06. The stock has a market cap of $283.71 million, a price-to-earnings ratio of 38.83 and a beta of 0.53. The company has a debt-to-equity ratio of 1.76, a current ratio of 3.58 and a quick ratio of 2.87.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The company had revenue of $49.88 million during the quarter, compared to analysts’ expectations of $51.99 million. Zynex had a return on equity of 13.14% and a net margin of 3.12%. Zynex’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $0.09 earnings per share. On average, equities research analysts expect that Zynex will post 0.51 earnings per share for the current year.

Hedge Funds Weigh In On Zynex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its position in Zynex by 358.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,458 shares of the company’s stock valued at $81,000 after acquiring an additional 5,830 shares in the last quarter. Mainstay Capital Management LLC ADV bought a new position in Zynex during the fourth quarter valued at approximately $118,000. State Board of Administration of Florida Retirement System bought a new position in Zynex during the first quarter valued at approximately $137,000. Principal Financial Group Inc. raised its position in Zynex by 56.4% during the first quarter. Principal Financial Group Inc. now owns 17,679 shares of the company’s stock valued at $219,000 after acquiring an additional 6,378 shares in the last quarter. Finally, BOKF NA bought a new position in Zynex during the first quarter valued at approximately $246,000. Institutional investors own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.